|
|
|
Registry of biomedical companies:
[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 460 active entries
9th Fl., No.108, Jhouzih St., Neihu District
Taipei, 114
Taiwan
Phone: +886-2-87511888
Fax: +886-2-6602-1218
E-Mail:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
Description:
Abnova, founded in Year 2002 and held its Initial Public Offering (IPO) in Taiwan in Year 2009, is the first biotech company successfully integrated the IT-style management and industrial-scale antibody manufacturing. It is also the world's largest antibody manufacturer. Rather than the traditional method of antibody production, Abnova is taking a genomic/proteomic approach for the antibody development. Our goal is to have at least one antibody to every human expressed gene in human genome. In Phase I of our business plans, we vastly expand the scope and availability of antibody reagents for the research market by taking a genome-wide approach to the high throughput production of human protein and antibody. We manufacture all our products, including recombinant proteins and antibodies, in our state-of-the-art production and SPF animal facilities. These products are marketed through a combination of E-commerce based direct sales and a multi-tiered, sales network of over 49 distributors. We are dedicated to providing our clients that from the academic institutions or industry the highest quality products and biomedical reagents to accelerating life science research and development. Leveraging on a solid foundation of antibody manufacturing, expanding antibody bank, and increasing customer base, Abnova continues to grow its business and products worldwide, at the same time establishing an unprecedented, global network of collaborators contributing to the next generation's product ideas and developments. Starting from Year 2009 to 2013, in Phase II of our business plans, we have diversified into the systems arena focusing on antibody pairs, ELISA kits and instrumentations for rare cell isolation. In Phase III (Year 2014 to 2016), we focus on in vitro diagnostic development concentrating on infection, cancer, endocrine and metabolism. In the future, phase IV (Year 2017 and later), we will focus on drug development specializing on therapeutic monoclonal antibody. The value-added business has set the path of company's future growth and provided an opportunity for Abnova to contribute to the biotech industry at large.
Selected Categories:
Last update of this entry: September 27, 2017
|